Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Lamarca, Ángela; H. Palmer, Daniel; Wasan, Harpreet; J. Ross, Paul; Ting, Yuk; Arora, Arvind; Falk, Stephen; Gillmore, Roopinder; Wadsley, Jonathan; Patel, Kinnari; Anthoney, Alan; Maraveyas, Anthony; Iveson, Timothy; S. Waters, Justin; Hobbs, Claire; Barber, Safia; David J. Ryder, W.; Ramage, John; Davies, Linda; Bridgewater, John; W. Valle, Juan

doi:10.1016/s1470-2045(21)00027-9

Public

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Published in The Lancet Oncology • Mar 30, 2021

Authors:

Ángela Lamarca

Daniel H. Palmer

Harpreet Wasan

Abstract

BACKGROUND: Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is the standard first-line chemotherapy regimen, but no robust evidence is available for second-line chemotherapy. The aim of this study was to determine the benefit derived from second-line FOLFOX (folinic aci...

Subject

FOLFOX

Biliary tract cancer

Open label

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!